Spruce Biosciences, Inc.

Equities

SPRB

US85209E1091

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
0.5621 ^USD	-4.73%		+2.69%	-80.82%

07-09	Spruce Biosciences, Inc. completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	CI
06-14	Spruce Biosciences, Inc. stalking horse asset purchase agreement to acquire Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	CI

Spruce Biosciences Appoints Javier Szwarcberg as Chief Executive Officer

January 05, 2022 at 08:00 am

Spruce Biosciences, Inc. announced that Dr. Javier Szwarcberg, M.D., MPH, has been appointed Chief Executive Officer. Dr. Javier Szwarcberg is an accomplished physician executive with over 18 years of leadership experience in the biotechnology and pharmaceutical industries. Most recently, Dr. Szwarcberg served as the Group Vice President and Head of Program and Portfolio Development for BioMarin Pharmaceuticals.

Latest news about Spruce Biosciences, Inc.

Spruce Biosciences, Inc. completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	07-08	CI
Spruce Biosciences, Inc. stalking horse asset purchase agreement to acquire Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.	06-13	CI
Oppenheimer Cuts Price Target on Spruce Biosciences to $3 From $4, Keeps Outperform Rating	06-13	MT
Transcript : Spruce Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 05:00 PM	06-05
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder	06-04	CI
Spruce Biosciences, Inc. Presents Phase 2 POWER Study Results of Tildacerfont for Treatment of Polycystic Ovary Syndrome at ENDO 2024	06-03	CI
Spruce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
North American Morning Briefing : Inflation -2-	03-15	DJ
Top Midday Decliners	03-14	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	03-14	MT
HC Wainwright Downgrades Spruce Biosciences to Neutral From Buy	03-14	MT
JMP Securities Adjusts Spruce Biosciences' Price Target to $3 From $8, Maintains Market Outperform Rating	03-14	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	03-14	MT
Leerink Partners Downgrades Spruce Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $9	03-14	MT
Guggenheim Downgrades Spruce Biosciences to Neutral From Buy	03-14	MT
Ladenburg Thalmann Downgrades Spruce Biosciences to Neutral From Buy	03-14	MT
Spruce Biosciences Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $2 From $9, Shares Plunge Pre-Bell; Speculative Risk Kept	03-14	MT
Spruce Biosciences 2023 Loss Narrows; to Cut 21% Workforce After Trial Misses Target; Shares Sink	03-13	MT
Transcript : Spruce Biosciences, Inc., 2023 Earnings Call, Mar 13, 2024	03-13
Spruce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13	CI
Spruce Biosciences, Inc. Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH	03-13	CI
RBC Lifts Price Target on Spruce Biosciences to $9 From $8, Cites Improved Chances of Congenital Adrenal Hyperplasia Program Success; Outperform, Speculative Risk Kept	02-26	MT
Guggenheim Initiates Spruce Biosciences at Buy Rating With $10 Price Target	02-21	MT
Top Premarket Decliners	02-13	MT
Spruce Biosciences, Inc. Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia	01-22	CI

Chart Spruce Biosciences, Inc.

Duration

Period

More charts

Company Profile

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Spruce Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5621 USD

Average target price

2.5 USD

Spread / Average Target

+344.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SPRUCE BIOSCIENCES, INC.	-80.82%	23.13M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+48.77%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research